Drug intelligence / Profile preview

fuzheng hejie granules

Development stage: Unknown
Lead developer: Shanghai Children's Medical Center
Administration: Oral

Overview

Fuzheng Hejie Granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Shanghai Children's Medical Center, affiliated with the Shanghai Jiao Tong University School of Medicine. It is primarily investigated for the treatment of asymptomatic COVID-19 in pediatric populations. The granules are designed based on TCM principles to strengthen the body's 'upright qi' (Fuzheng) and harmonize the internal environment (Hejie) to promote viral clearance and prevent symptom development. Clinical evaluation of the formulation has focused on its impact on viral shedding duration, changes in viral load (CT values), and long-term lung function recovery in children.

Other names: Fuzheng Hejie Granules

Beyond the preview

Go deeper on fuzheng hejie granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fuzheng hejie granules.

Explore the full profile